Curve Therapeutics Ltd. has raised £40.5 million (US$51.2 million) in a series A round to take two lead programs toward the clinic over the next three years. Since its formation in 2019, Curve has applied its Microcycle intracellular screening platform to discover a pipeline of small molecules against oncology targets that have evaded conventional approaches.
MYC oncogene is known to be amplified in 5% to 10% and overexpressed in 20% of clear cell renal cell carcinoma (ccRCC), conferring aggressiveness. Researchers have now found...
Researchers from Baylor University and collaborators have described the synthesis and evaluation of a series of 6-aryl-3-aroyl-indole analogues acting as tubulin polymerization inhibitors aimed to be used as anticancer agents. Inhibitors of tubulin polymerization are promising antiproliferative agents and their interaction with the colchicine site is linked to its activity as vascular disrupting agents (VDAs).
Jiangxi Jemincare Group Co. Ltd. has reported that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co. Ltd., recently received approvals for clinical trials of five of its drugs in the fields of cancer, kidney and infectious diseases.
One of the difficulties for preventing the evolution of a tumor is that cancer progression can be promoted by undifferentiated or migrating cells whose states could follow different directions. At the 40th edition of Barcelona Biomed conferences at the Institute for Research in Biomedicine (IRB Barcelona), which took place from Nov. 27 to 29, 2023, and is entitled “Cancer in Context: Cellular, Tissue, and Organismal Determinants of Malignant Fates,” Angela Nieto presented her latest data on epithelial-to-mesenchymal transition (EMT).
Aravive Inc.’s sole asset missed a phase III primary endpoint in ovarian cancer but the company still has studies planned for treating renal cell carcinoma and pancreatic cancer. Aravive’s stock (NASDAQ:ARAV) dwindled dramatically on Aug. 3, with shares closing 77.2% lower at 28 cents each. That’s a massive drop from heights seen in the past 12 months, as shares hit $2.46 each in March 2023 and $2.09 each in November 2022. The company plans to study the data and make a decision about whether to proceed with the other studies.
Researchers from Hibercell Inc. presented preclinical data for the eukaryotic translation initiation factor 2-α kinase 3 (PERK) inhibitor HC-5404, currently in phase I development for the treatment of solid tumors (NCT04834778).
Human natural killer (NK) cells play an essential role in tumor surveillance and can attack malignant cells in an antigen-independent manner. Because of this, allogeneic NK cells can be engineered as off-the-shelf therapies and may be used to target different hematological malignancies or solid tumors.
Voltron Therapeutics Inc., a portfolio company of Lucius Partners LLC, has signed a new sponsored research agreement (SRA) with the Vaccine and Immunotherapy Center at Massachusetts General Hospital (MGH), Harvard Medical School to initiate a preclinical immuno-oncology study targeting prostate stem cell antigen (PSCA) in prostate, renal cell and urothelial cancers.
